Veristat Acquires European Medical Writing Consultancy Scinopsis
Summary
The acquisition strengthens Veristat’s ability to meet growing client demand in one of its highest-valued service areas as the range of clinical trial content expands and the importance of regulatory documentation increases. “Effective medical writing in the clinical and regulatory realm has always been important, yet with the increasing complexity of todays diverse scientific solutions and novel therapeutics it is essential,” said Patrick Flanagan, Chief Executive Officer of Veristat. “Quality medical writing is unquestionably key to having productive engagement no matter the therapeutic category, audience, or document type,” stated Dr. Sarah Hopwood, Chief Operating Officer of Scinopsis. The combination of the Scinopsis team with our experienced medical writing team will provide our clients with a global approach to the complexities of successful regulatory writing.” More information on Veristat’s medical writing services can be found at https://www.veristat.com/services/regulatory-affairs/medical-writing Veristat, a scientific-minded global clinical research organization (CRO) enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. Based in Fréjus, France with an office in Brighton, UK, Scinopsis is guided by an unwavering focus on quality, the highest levels of scientifically rigorous content, flexibility to meet stringent timelines, consistent communication, and proactive project management.